Latest NewsFDA NewsAdverse Event ManagementSupportive CareDisparities in Cancer CareDrug SafetyRadiation OncologySurvivorship Practice ManagementPreventionContributorsSponsored
Expert ConnectionsMorning RoundsThe VitalsPodcastsVideosBetween the LinesMeeting of the MindsTraining Academy
Conference CoverageConference Listing
Publications
Continuing Education
Case-Based Digest Rx Road MapWebinarsCancer Summary SlidesMPN Symptom ManagementEvents
SubscribePartners
Brain Cancer
Breast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head and Neck Cancers
HematologyHematologyHematologyHematologyHematologyHematology
Lung Cancer
Pediatric Cancer
Sarcomas
Skin CancerSkin Cancer
Advanced Practice Corner Logo
    Brain Cancer
    Breast CancerBreast Cancer
    Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
    Genitourinary CancerGenitourinary CancerGenitourinary CancerGenitourinary Cancer
    Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
    Head and Neck Cancers
    HematologyHematologyHematologyHematologyHematologyHematology
    Lung Cancer
    Pediatric Cancer
    Sarcomas
    Skin CancerSkin Cancer
    Advanced Practice Corner Logo
        • Publications
        • Subscribe
        • Partners
      Advertisement

      Trends in Colon Cancer

      January 5, 2015
      By Lisa Schulmeister, MN, RN, ACNS-BC, OCN , FAAN
      Article

      Decline seen for older adults but rates are rising for young adults.

      Researchers from the University of Texas M.D. Anderson Cancer Center in Houston conducted a large retrospective cohort study of colon cancer using the Surveillance, Epidemiology, and End Results registry. Age at diagnosis was analyzed in 15-year intervals starting at the age of 20. Data included all 393,241 patients diagnosed with colon or rectal cancer (CRC) from January 1, 1975 through December 31, 2010.

      The overall age-adjusted CRC incidence rate decreased by 0.92% between 1975 and 2010, and there was a steady decline in the incidence of CRC in people age 50 years or older; however, the opposite trend was observed for young adults. For patients aged 20 to 34, the incidence rates of localized, regional, and distant colon and rectal cancers have increased. If the current trends continue, there will be rise in colon cancer incidence among young adults by 2030. The incidence is expected to increase by 90% for individuals who are age 20 to 124% for those who are 34 years old. The researchers concluded that further studies are needed to determine the cause for these trends and identify potential preventive and early detection strategies. They noted that behavioral factors, such as obesity and physical inactivity, may play a role in the increasing incidence of CRC among young people, and the typical modern diet high in red meat and processed foods also may play a role in the rising incidence.

      Reference

      Bailey CE et al. Increasing Disparities in the Age-Related Incidences of Colon and Rectal Cancers in the United States, 1975-2010. JAMA Surg. Published online 11/5/14, doi:10.1001/jamasurg.2014.1756.

      Newsletter

      Stay up to date on recent advances in oncology nursing and patient care.

      Subscribe Now!
      Recent Videos
      a man wearing a suit and tie in front of a green screen with the ONN logo
      Karyn Goodman
      Expert in oncology
      Expert in oncology
      Experts in oncology
      Expert in oncology
      Expert in oncology
      Expert in oncology
      Expert in oncology
      Related Content

      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Graphic reading "FDA APPROVED" resembling a seal of approval

      Retifanlimab Receives FDA Approval for Advanced Anal Cancer

      Bridget Hoyt
      May 15th 2025
      Article

      Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Graphic reading "FDA APPROVED" resembling a stamp of approval

      Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

      Bridget Hoyt
      March 26th 2025
      Article

      The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.


      Image of a vaccine being prepared by a person in a white coat and blue gloves

      Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC

      Kyle Doherty
      Published: March 24th 2025 | Updated: March 24th 2025
      Article

      Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

      Related Content

      Illustration of a pancreas on a blue background

      Novel ADC Receives FDA Fast Track Designation for Pancreatic Cancer

      Sabrina Serani
      May 30th 2025
      Article

      The novel antibody-drug conjugate EBC-129 has been fast tracked by the FDA for approval in pancreatic ductal adenocarcinoma.


      The Vitals

      ctDNA Monitoring is a Piece of the Puzzle in CRC Treatment

      Lindsay Fischer
      October 31st 2023
      Podcast

      Holly Chitwood, DNP, FNP-C, AGACNP-BC, explains how circulating tumor DNA monitoring helps providers screen minimal residual disease in individuals with colorectal cancer.


      Graphic reading "FDA APPROVED" resembling a seal of approval

      Retifanlimab Receives FDA Approval for Advanced Anal Cancer

      Bridget Hoyt
      May 15th 2025
      Article

      Retifanlimab has received approval for the frontline treatment of advanced anal cancer from the FDA.


      The Vitals

      Terri Pollack Offers Perspective on 2023 ASCO GI Cancers Symposium

      Lindsay Fischer
      March 1st 2023
      Podcast

      In this episode of "The Vitals," Terri Pollack, DNP, APRN, FNP-C, PMHNP-BC, underscores potentially practice-changing data which were presented during the 2023 GI Cancers Symposium.


      Graphic reading "FDA APPROVED" resembling a stamp of approval

      Cabozantinib Approved for Unresectable, Advanced/Metastatic epNET and pNET

      Bridget Hoyt
      March 26th 2025
      Article

      The FDA approved cabozantinib for use in patients with previously treated unresectable, locally advanced or metastatic, well-differentiated epNETs or pNETs.


      Image of a vaccine being prepared by a person in a white coat and blue gloves

      Maintenance OSE2101 With Chemo Reaches Primary OS End Point in PDAC

      Kyle Doherty
      Published: March 24th 2025 | Updated: March 24th 2025
      Article

      Maintenance treatment with OSE2101 plus FOLFIRI following induction chemotherapy with FOLFIRINOX yielded promising results in patients with advanced/metastatic PDAC.

      Latest Conference Coverage

      Relacorilant Combo Boosts PFS in Resistant Ovarian Cancer

      Nivolumab/Ipilimumab To Be New MSI-H/dMMR mCRC Standard of Care

      T-DXd PFS Benefit Significant Across HR+, HER2-Low Breast Cancer Mutations

      AI Tool May Predict Response, Resistance in Advanced RCC

      View More Latest Conference Coverage
      About Us
      Editorial Board
      Contact Us
      CancerNetwork.com
      CureToday.com
      OncLive.com
      TargetedOnc.com
      Advertise
      Privacy
      Terms & Conditions
      Do Not Sell My Information
      Contact Info

      2 Commerce Drive
      Cranbury, NJ 08512

      609-716-7777

      © 2025 MJH Life Sciences

      All rights reserved.